BIM
115.5
+1.49%↑
SRT3
228.3
-0.7%↓
GXI
55.3
+2.88%↑
ICAD
21.08
-0.57%↓
BIM
115.5
+1.49%↑
SRT3
228.3
-0.7%↓
GXI
55.3
+2.88%↑
ICAD
21.08
-0.57%↓
BIM
115.5
+1.49%↑
SRT3
228.3
-0.7%↓
GXI
55.3
+2.88%↑
ICAD
21.08
-0.57%↓
BIM
115.5
+1.49%↑
SRT3
228.3
-0.7%↓
GXI
55.3
+2.88%↑
ICAD
21.08
-0.57%↓
BIM
115.5
+1.49%↑
SRT3
228.3
-0.7%↓
GXI
55.3
+2.88%↑
ICAD
21.08
-0.57%↓
24u
Huidig
Min
119.7
Max
122.55
Inkomsten | -142M 667M |
---|---|
Verkoop | 152M 5.4B |
K/W Sectorgemiddelde | 26.27 57.333 |
EPS | 2.2 |
Dividendrendement | 1.34 |
Winstmarge | 12.311 |
EBITDA | 85M 1.6B |
Aanbevelingen | Buy |
---|---|
12 Maanden Prognose | +38.83% upside |
Dividendrendement Sectorgemiddelde | 1.34% 2.63% |
---|---|
Volgende Winsten | 15 mei 2025 |
Marktkapitalisatie | 33B 98B |
---|---|
Vorige openingsprijs | 119.98 |
Vorige sluitingsprijs | 121.4 |
By Trading Central
Vertrouwen
Very Strong Bullish Evidence
117.55 / 120.4 Steun & Weerstand
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
6 mrt 2025, 06:27 UTC
Merck KGaA Forecasts Earnings, Sales Growth After In-Line Results
DJ
Lezen
11 feb 2025, 07:03 UTC
Germany's Merck in Talks to Buy SpringWorks Therapeutics
DJ
Lezen
10 feb 2025, 16:38 UTC
SpringWorks Therapeutics Shares Rise on Report it May be Acquired
DJ
Lezen
24 apr 2025, 22:51 UTC
Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update
DJ
Lezen
24 apr 2025, 20:54 UTC
Merck KGaA: No Final Decision Has Been Taken; No Legally Binding Agreement Has Been Entered Into
DJ
Lezen
24 apr 2025, 20:50 UTC
Merck KGaA Confirms Late-Stage Discussions With SpringWorks Therapeutics on Potential Acquisition for About 47c a Share
DJ
Lezen
24 apr 2025, 19:05 UTC
Merck KGaA Expected to Pay Close to $47 a Share for SpringWorks, Sources Say -- WSJ
DJ
Lezen
24 apr 2025, 19:05 UTC
Merck KGaA, SpringWorks Deal Expected to Be Finalized as Soon as Monday, Sources Say -- WSJ
DJ
Lezen
24 apr 2025, 19:05 UTC
Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- WSJ
DJ
Lezen
24 apr 2025, 19:05 UTC
Merck KGaA Nears Roughly $3.5 Billion Takeover of SpringWorks Therapeutics, Sources Say -- WSJ
DJ
Lezen
6 mrt 2025, 11:18 UTC
Impact from U.S. Tariffs Is Manageable for Merck KGaA, CEO Says -- Market Talk
DJ
Lezen
6 mrt 2025, 11:14 UTC
Merck KGaA's Outlook Signals Greater Transparency -- Market Talk
DJ
Lezen
6 mrt 2025, 08:20 UTC
Merck KGaA's Earnings Guidance Seems Soft Amid Semiconductor Uncertainty -- Market Talk
DJ
Lezen
6 mrt 2025, 06:00 UTC
Merck KGaA Expects 2025 Net Sales Between EUR21.5B and EUR22.9B
DJ
Lezen
6 mrt 2025, 06:00 UTC
Merck KGaA 2024 Adj EPS EUR8.63
DJ
Lezen
6 mrt 2025, 06:00 UTC
Merck KGaA Expects 2025 EBITDA Before One-Time Items Between EUR6.1B and EUR6.6B
DJ
Lezen
6 mrt 2025, 06:00 UTC
Merck KGaA 2024 EBIT EUR3.645B
DJ
Lezen
6 mrt 2025, 06:00 UTC
Merck KGaA 2024 After-Tax Profit EUR2.79B
DJ
Lezen
6 mrt 2025, 06:00 UTC
Merck KGaA 2024 Ebitda Before One-Time Items EUR6.07B
DJ
Lezen
6 mrt 2025, 06:00 UTC
Merck KGaA 2024 EBITDA EUR5.78B
DJ
Lezen
6 mrt 2025, 06:00 UTC
Merck KGaA 2024 Sales EUR21.16B
DJ
Lezen
6 mrt 2025, 06:00 UTC
Merck KGaA Keeps Dividend at EUR2.20
DJ
Lezen
6 mrt 2025, 06:00 UTC
Analysts Saw Merck KGaA 2024 Sales at EUR21.14B
DJ
Lezen
6 mrt 2025, 06:00 UTC
Analysts Saw Merck KGaA 2024 Ebitda Before One-Time Items at EUR6.08B
DJ
Lezen
11 feb 2025, 16:45 UTC
Merck's Potential Springworks Deal Unlikely to Move Needle on Earnings -- Market Talk
DJ
Lezen
11 feb 2025, 10:54 UTC
Germany's Merck Potential Buy of SpringWorks Therapeutics Puts Its Strategy Into Question -- Market Talk
DJ
Lezen
11 feb 2025, 10:52 UTC
German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk
DJ
Lezen
6 jan 2025, 13:08 UTC
Merck KGaA: Transaction closed on Dec. 23, 2024
DJ
Lezen
6 jan 2025, 13:07 UTC
Merck KGaA: Didn't Disclose Financial Details
DJ
Lezen
6 jan 2025, 13:06 UTC
Merck KGaA: HUB's Organoid Offering Complements Merck KGaA's Cell Culture Portfolio
DJ
Lezen
Prijswijziging
By TipRanks
12 Maanden Prognose
Gemiddelde 166.25 EUR 38.83%
Hoogste 190 EUR
Laagste 107 EUR
Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merck KGaA - Dist. in de afgelopen 3 maanden.
By TipRanks
Buy
9 ratings
6
Buy
2
Hold
1
Sell
Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Merck KGaA - Dist in de afgelopen 3 maanden.
By Trading Central
Korte Termijn
Very Strong Bullish Evidence
Recent bullish events outweigh bearish events.
Gemiddeld Termijn
Bearish Evidence
All events are bearish.
Lange Termijn
Bearish Evidence
All events are bearish.
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$